Adage Capital Partners’s Apogee Therapeutics APGE Stock Holding History

Adage Capital Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.2M	Hold	250,000	–	–	0.05%	365
2026 Q1	$21M	Buy	250,000 +10,000	+4%	+$726K	0.03%	457
2025 Q4	$18.1M	Buy	240,000 +5,000	+2%	+$315K	0.03%	517
2025 Q3	$9.34M	Sell	235,000 -1,055,464	-82%	-$40.3M	0.01%	646
2025 Q2	$56M	Buy	1,290,464 +563,464	+78%	+$21.4M	0.09%	210
2025 Q1	$27.2M	Buy	727,000 +486,800	+203%	+$18.8M	0.05%	348
2024 Q4	$10.9M	Buy	+240,200	New	+$12.3M	0.02%	583
2024 Q3	–	Sell	-50,000	Closed	-$1.97M	–	871
2024 Q2	$1.97M	Sell	50,000 -125,000	-71%	-$6.07M	﹤0.01%	780
2024 Q1	$11.6M	Sell	175,000 -350,000	-67%	-$15.3M	0.02%	572
2023 Q4	$14.7M	Buy	525,000 +150,000	+40%	+$3.01M	0.03%	512
2023 Q3	$7.99M	Buy	+375,000	New	+$8.26M	0.02%	608

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Adage Capital Partners's APGE Position: Q2 2026 in Review

Adage Capital Partners held its Apogee Therapeutics (APGE) position steady in Q2 2026 at 250,000 shares worth $33.2M. The position accounts for 0.05% of the portfolio, ranked #365.

Adage Capital Partners first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. The position peaked at $56M in Q2 2025. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

Adage Capital Partners held 250,000 shares of Apogee Therapeutics worth $33.2M as of Q2 2026.
Adage Capital Partners left its Apogee Therapeutics share count unchanged in Q2 2026.
Apogee Therapeutics made up 0.05% of Adage Capital Partners's portfolio in Q2 2026, its #365 holding.
Adage Capital Partners first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
Adage Capital Partners's Apogee Therapeutics position peaked at $56M in Q2 2025.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.